COMP <GO>
UNH vs ABBV // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
UnitedHealth Group Incorporated (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: UNH 5
— ABBV 8
■ METRIC PARITY
LAST: $406.97 (-0.96%) • MKT CAP: $368.83B
options-implied-move
6.74%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UNH VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UNH | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.57% | 70.20% | +18.37 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.47% | 29.00% | -17.53 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 16.4x | 33.3x | -16.85 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 6.48% | 3.47% | +3.01 | UNH | /fcf-yield <GO> |
| Operating Margin | 4.82% | 24.60% | -19.78 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 3.14% | 6.90% | -3.76 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 6.46% | 8.60% | -2.14 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.28% | 2.27% | +0.01 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.12 | 5.33 | -2.21 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 6.74% | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.2 | 65.1 | -5.90 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.33 | 1.15 | -0.82 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.7x | 113.1x | -95.36 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $368.83B | $513.86B | -$145.03B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UNH REV | ABBV REV | UNH GROSS % | ABBV GROSS % | UNH FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $447.57B | $61.16B | 88.7% | 70.2% | $16.07B | $17.82B |
| FY 2024 | $400.28B | $56.33B | 88.3% | 70.0% | $20.70B | $17.83B |
| FY 2023 | $371.62B | $54.32B | 89.6% | — | $25.68B | $20.39B |
| FY 2022 | $324.16B | — | 89.6% | — | $23.40B | — |
| FY 2021 | $287.60B | — | 89.2% | — | $19.89B | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UNH // BETA 0.33
ABBV // BETA 1.15